Allogene Therapeutics, Inc.
ALLO
$1.78
-$0.09-4.57%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | -31.95% | -30.64% | -21.92% | -17.57% | -11.42% |
| Gross Profit | 34.53% | 30.64% | 21.91% | 17.56% | 11.39% |
| SG&A Expenses | 2.15% | -11.20% | -12.92% | -12.53% | -9.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.31% | -25.81% | -19.64% | -16.32% | -10.97% |
| Operating Income | 25.23% | 25.81% | 19.63% | 16.31% | 10.95% |
| Income Before Tax | 30.01% | 31.01% | 25.77% | 25.35% | 15.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.14% | 31.14% | 25.90% | 25.20% | 15.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.14% | 31.14% | 25.90% | 25.20% | 15.22% |
| EBIT | 25.23% | 25.81% | 19.63% | 16.31% | 10.95% |
| EBITDA | 26.20% | 26.79% | 20.21% | 16.66% | 10.93% |
| EPS Basic | 40.16% | 37.45% | 34.96% | 37.10% | 31.15% |
| Normalized Basic EPS | 35.93% | 33.54% | 31.20% | 30.52% | 29.29% |
| EPS Diluted | 40.16% | 37.45% | 34.96% | 37.10% | 31.15% |
| Normalized Diluted EPS | 35.93% | 33.54% | 31.20% | 30.52% | 29.29% |
| Average Basic Shares Outstanding | 19.11% | 9.96% | 13.28% | 17.68% | 22.86% |
| Average Diluted Shares Outstanding | 19.11% | 9.96% | 13.28% | 17.68% | 22.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |